REG - Optima Health PLC - First Day of Dealings on AIM

Optima HealthAnnouncement

26/09/2024 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240926:nRSZ7106Fa&default-theme=true

RNS Number : 7106F  Optima Health PLC  26 September 2024

 

 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR
INDIRECTLY IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE
A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION.

 

This announcement does not constitute or form part of an offer to sell or
issue or a solicitation of an offer to subscribe for or buy any securities nor
should it be relied upon in connection with any contract or commitment
whatsoever in any jurisdiction. Investors should not subscribe for or purchase
any securities referred to in this announcement except solely on the basis of
the information contained in the admission document, including the risk
factors set out therein, published by Optima Health plc (the "Company" or
"Optima") on 23 September 2024 in connection with the admission of the
ordinary shares in the capital of the Company to trading on AIM, a market
operated by London Stock Exchange plc (the "Admission Document").

 

 

Optima Health plc

("Optima", the "Company", and, together with its subsidiaries, the "Group")

 

First Day of Dealings on AIM

 

-      UK's largest provider of corporate health and wellbeing solutions

-      Cash generative and profitable (on adjusted basis)

-     FY2024 revenues of 110.9 million and adjusted EBITDA of £18.0
million

 

LONDON, UK., 26 September 2024, Optima Health, the UK's leading provider of
technology enabled corporate health and wellbeing solutions, is pleased to
announce the admission of its Ordinary Shares to trading on AIM, a market
operated by London Stock Exchange plc ("Admission").

 

Dealings in the Company's ordinary shares of £0.01 each in the capital of the
Company ("Ordinary Shares") will commence at 8.00 a.m. today under the ticker
"OPT" (ISIN:  GB00BRSCY602). On Admission, the Company will have 88,776,226
Ordinary Shares in issue and no Ordinary Shares held in treasury.

 

Jonathan Thomas, Chief Executive Officer of Optima Health, commented: "We are
delighted to begin Optima Health's journey as an AIM-listed company. As an
independent business, we are well positioned to continue our successful track
record of growth, both organic and through successful acquisition and
integration, within the strong and growing occupational health market in the
UK. Being a publicly listed company will provide us with an opportunity to
build and deliver significant value for our shareholders and employees and we
look forward to beginning this exciting new chapter in our story."

 

Admission

The Directors believe that Admission will be an important step in the Group's
development and will assist the Group in its development by raising its public
profile, widening its shareholder base, providing potential future access to
development capital to progress its current and future pipeline of proprietary
products and enabling it to expand within its core areas and expand its
commercial partnerships. It will also provide the Group with the ability to
incentivise its employees through share incentive plans, which should assist
it in continuing to attract, retain and motivate high calibre employees.

 

No new capital was raised through an offer or sale of Ordinary Shares to
institutional investors or the public in connection with Admission. Prior to
Admission, the Optima Health executive management team subscribed for new
Ordinary Shares in the Company, in connection with the settlement of the
Company's legacy senior management share incentive plan, as further described
in the Admission Document.

 

Unless otherwise indicated, capitalised terms in this Announcement have the
meaning given to them in the Admission Document.

 

 

Enquiries

 

 Optima Health                                   +44(0)3300085113

 Jonathan Thomas, CEO                            media@OptimaHealth.co.uk

 Heidi Giles, CFO

 Nominated Adviser and Corporate Broker

 Panmure Liberum Limited                         +44 (0)20 3100 2000

 Emma Earl / Will Goode/ Mark Rogers

 Rupert Dearden

 UK Financial PR Adviser                         optimahealth@icrinc.com

 ICR Consilium

 Mary-Jane Elliott / Angela Gray / Chris Welsh

 

 

About Optima Health

Optima Health is the UK's leading provider of occupational health and
wellbeing services, directly influencing and improving people's lives for 25
years. Optima Health's incredible team of professionals quickly and
effectively encapsulate client's needs, supporting organisations of all shapes
and sizes. Through tailored solutions and innovative systems, Optima Health
offers unparalleled clinical expertise to its clients. These solutions ensure
that processes are simple and allow its clients to spend more time focusing on
their employees driving a healthy, high-performing workplace. For more
information visit www.optimahealth.co.uk (http://www.optimahealth.co.uk) .

 

 

 

IMPORTANT NOTICES

 

This announcement does not constitute, or form part of, any offer or
invitation to sell, allot or issue, or any solicitation of any offer to
purchase or subscribe for, any securities in the Company in any jurisdiction
nor shall it, or any part of it, or the fact of its distribution, form the
basis of, or be relied on in connection with or act as an inducement to enter
into, any contract or commitment therefor.

 

No reliance may be placed, for any purpose whatsoever, on the information or
opinions contained in this announcement or on its accuracy, fairness or
completeness. To the fullest extent permitted by applicable law or regulation,
no undertaking, representation or warranty, express or implied, is given by or
on behalf of the Company, Panmure Liberum Limited ("Panmure Liberum"), or
their respective parent or subsidiary undertakings or the subsidiary
undertakings of any such parent undertakings or any of their respective
directors, officers, partners, employees, agents, affiliates, representatives
or advisers or any other person as to the accuracy, sufficiency, completeness
or fairness of the information, opinions or beliefs contained in this
announcement and no responsibility or liability is accepted by any of them for
any errors, omissions or inaccuracies in such information, opinions or beliefs
or for any loss, cost or damage suffered or incurred, howsoever arising, from
any use, as a result of the reliance on, or otherwise in connection with, this
announcement.

 

Panmure Liberum, which is authorised and regulated by the Financial Conduct
Authority is acting only for the Company in connection with Admission and is
not acting for or advising any other person, or treating any other person as
its client, in relation thereto, or giving advice to any other person in
relation to the matters contained herein. Such persons should seek their own
independent legal, investment and tax advice as they see fit. Panmure
Liberum's responsibilities, as the Company's nominated adviser under the AIM
Rules for Nominated Advisers and AIM Rules for Companies will be owed solely
to the London Stock Exchange and not to the Company, to any of its directors
or to any other person in respect of a decision to subscribe for or otherwise
acquire Shares in reliance on the Admission Document. No representation or
warranty, express or implied, is made by Panmure Liberum or the Company or
their respective affiliates, directors, officers, employees or advisers as to
any of its contents.

 

This announcement does not form the basis of or constitute any offer or
invitation to sell or issue, or any solicitation of any offer to purchase or
subscribe for any Shares or any other securities nor shall it (or any part of
it) or the fact of its distribution, form the basis of, or be relied on in
connection with, any contract or commitment therefor. No offer or sale of the
Shares has been and will not be registered under the applicable securities
laws of the United States, Australia, Canada, Japan or South Africa. Subject
to certain exceptions, the Shares may not be offered or sold in the United
States, Australia, Canada, Japan or South Africa or to, or for the account or
benefit of, any national, resident or citizen of the United States, Australia,
Canada, Japan or South Africa. There will be no public offer of the Shares in
the United States, Australia, Canada, Japan or South Africa.

 

This announcement may include statements that are, or may be deemed to be,
"forward-looking statements". These forward-looking statements may be
identified by the use of forward-looking terminology, including the terms
"believes", "estimates", "plans", "projects", "anticipates", "expects",
"intends", "may", "will" or "should" or, in each case, their negative or other
variations or comparable terminology, or by discussions of strategy, plans,
objectives, goals, future events or intentions. These statements reflect
beliefs of the Directors (including based on their expectations arising from
pursuit of the Company's strategy) as well as assumptions made by the
Directors and information currently available to the Company. Although the
Directors consider that these beliefs and assumptions are reasonable, by their
nature, forward-looking statements involve known and unknown risks,
uncertainties, assumptions and other factors that may cause the Company's
actual financial condition, results of operations, cash flows, liquidity or
prospects to be materially different from any future such metric expressed or
implied by such statements. Past performance cannot be relied upon as a guide
to future performance and should not be taken as a representation that trends
or activities underlying past performance will continue in the future.
Forward-looking statements speak only as of the date they are made. No
representation is made or will be made that any forward-looking statements
will come to pass or prove to be correct.

 

Whilst the contents of this announcement are believed to be true and accurate
as at the date of its publication, no representation or warranty is made as to
such contents continuing to be true and accurate at any point in the future.

 

For the avoidance of doubt, the contents of the Company's websites and social
media accounts are not incorporated by reference into, and do not form part
of, this announcement.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFELLLZKLBBBQ